Research Topic

Insights in Genome Engineering and Neurologic Disorders: 2021

About this Research Topic

This Research Topic is part of the Insights in Frontiers in Genome Editing series. Other titles in the series are:

Insights in Genome Editing in Plants: 2021
Insights in Genome Editing Tools and Mechanisms: 2021

We are now entering the third decade of the 21st Century, and, especially in the last years, the achievements made by scientists have been exceptional, leading to major advancements in the fast-growing field of genome editing applied across neuroscience, neurology and psychiatry. Frontiers has organized a series of Research Topics to highlight the latest advancements in science in order to be at the forefront of science in different fields of research. This editorial initiative of particular relevance, led by Dr. David Segal, Specialty Chief Editor of the Genome Engineering and Neurologic Disorders section, together with Dr. Marta Olejniczak and Dr. Mikhail Stepanichev, is focused on new insights, novel developments, current challenges, latest discoveries, recent advances and future perspectives in the field of genome editing.

The Research Topic solicits brief, forward-looking contributions from the editorial board members that describe the state of the art, outlining recent developments and major achieved accomplishments, future challenges and how to address those challenges to move the field forward. Reviews, Mini-Reviews, Perspectives, Brief Research Reports and Opinions summarizing the current state and future directions of the field are particularly welcome in this collection. This article collection will inspire, inform and provide direction and guidance to researchers in the field.

Please note that this article collection is open to receive primarily manuscripts from editorial board members. However, should you be interested in joining the board and/or wish to propose a spontaneous article that fits the scope of this project perfectly, please contact the editorial office first (genomeediting@frontiersin.org).

Marta Olejniczak is employed as the Director of Gene Therapy R&D at Dystrogen Gene Therapies Inc. Chicago, IL.


Keywords: Genome Editing, Genome Engineering, CRISPR, Gene Therapy, Neurology, Neurologic Disorders, Psychiatry, Neuroscience


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

This Research Topic is part of the Insights in Frontiers in Genome Editing series. Other titles in the series are:

Insights in Genome Editing in Plants: 2021
Insights in Genome Editing Tools and Mechanisms: 2021

We are now entering the third decade of the 21st Century, and, especially in the last years, the achievements made by scientists have been exceptional, leading to major advancements in the fast-growing field of genome editing applied across neuroscience, neurology and psychiatry. Frontiers has organized a series of Research Topics to highlight the latest advancements in science in order to be at the forefront of science in different fields of research. This editorial initiative of particular relevance, led by Dr. David Segal, Specialty Chief Editor of the Genome Engineering and Neurologic Disorders section, together with Dr. Marta Olejniczak and Dr. Mikhail Stepanichev, is focused on new insights, novel developments, current challenges, latest discoveries, recent advances and future perspectives in the field of genome editing.

The Research Topic solicits brief, forward-looking contributions from the editorial board members that describe the state of the art, outlining recent developments and major achieved accomplishments, future challenges and how to address those challenges to move the field forward. Reviews, Mini-Reviews, Perspectives, Brief Research Reports and Opinions summarizing the current state and future directions of the field are particularly welcome in this collection. This article collection will inspire, inform and provide direction and guidance to researchers in the field.

Please note that this article collection is open to receive primarily manuscripts from editorial board members. However, should you be interested in joining the board and/or wish to propose a spontaneous article that fits the scope of this project perfectly, please contact the editorial office first (genomeediting@frontiersin.org).

Marta Olejniczak is employed as the Director of Gene Therapy R&D at Dystrogen Gene Therapies Inc. Chicago, IL.


Keywords: Genome Editing, Genome Engineering, CRISPR, Gene Therapy, Neurology, Neurologic Disorders, Psychiatry, Neuroscience


Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Topic Editors

Loading..

Submission Deadlines

21 August 2021 Abstract
30 November 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..

Topic Editors

Loading..

Submission Deadlines

21 August 2021 Abstract
30 November 2021 Manuscript

Participating Journals

Manuscripts can be submitted to this Research Topic via the following journals:

Loading..
Loading..

total views article views article downloads topic views

}
 
Top countries
Top referring sites
Loading..